Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

  • The following terms were not found in PubMed: csg452[ti], deberza[ti], apleway[ti].
1.

Safety and Effectiveness of Tofogliflozin in Elderly Japanese Patients with Type 2 Diabetes Mellitus: a Post-Marketing Study (J-STEP/EL Study).

Utsunomiya K, Shimmoto N, Senda M, Kurihara Y, Gunji R, Fujii S, Kakiuchi S, Fujiwara H, Kameda H, Tamura M, Kaku K.

J Diabetes Investig. 2017 Jan 20. doi: 10.1111/jdi.12626. [Epub ahead of print]

2.
3.

Pharmacological analysis of SGLT2 inhibitor (tofogliflozin) using in vivo glucose clamp and titration protocols in rats and cynomolgus monkeys.

Fukazawa M, Nagata T, Suzuki M, Suzuki Y, Kawabe Y.

Nihon Yakurigaku Zasshi. 2016;148(5):259-265. No abstract available.

PMID:
27803439
4.
5.

Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes.

Pafili K, Maltezos E, Papanas N.

Expert Opin Drug Metab Toxicol. 2016 Sep 8:1-14. [Epub ahead of print]

PMID:
27558967
6.
7.

Development and validation of an LC-MS/MS method for the determination of tofogliflozin in plasma and its application to a pharmacokinetic study in rats.

Kobuchi S, Matsuno M, Fukuda E, Ito Y, Sakaeda T.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Aug 1;1027:227-33. doi: 10.1016/j.jchromb.2016.05.053.

PMID:
27304784
8.

Japanese study of tofogliflozin with type 2 diabetes mellitus patients in an observational study of the elderly (J-STEP/EL): A 12-week interim analysis.

Utsunomiya K, Shimmoto N, Senda M, Kurihara Y, Gunji R, Kameda H, Tamura M, Mihara H, Kaku K.

J Diabetes Investig. 2016 Sep;7(5):755-63. doi: 10.1111/jdi.12513.

9.

Development of a Scalable Synthesis of Tofogliflozin.

Ohtake Y, Emura T, Nishimoto M, Takano K, Yamamoto K, Tsuchiya S, Yeu SY, Kito Y, Kimura N, Takeda S, Tsukazaki M, Murakata M, Sato T.

J Org Chem. 2016 Mar 4;81(5):2148-53. doi: 10.1021/acs.joc.5b02734.

PMID:
26871504
10.

Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice.

Obata A, Kubota N, Kubota T, Iwamoto M, Sato H, Sakurai Y, Takamoto I, Katsuyama H, Suzuki Y, Fukazawa M, Ikeda S, Iwayama K, Tokuyama K, Ueki K, Kadowaki T.

Endocrinology. 2016 Mar;157(3):1029-42. doi: 10.1210/en.2015-1588.

PMID:
26713783
11.

A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus.

Ikeda S, Takano Y, Cynshi O, Tanaka R, Christ AD, Boerlin V, Beyer U, Beck A, Ciorciaro C, Meyer M, Kadowaki T.

Diabetes Obes Metab. 2015 Oct;17(10):984-93. doi: 10.1111/dom.12538.

PMID:
26179482
12.

A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.

Kasahara N, Fukase H, Ohba Y, Saito T, Miyata K, Iida S, Takano Y, Ikeda S, Harigai M, Terao K.

Drug Res (Stuttg). 2016 Feb;66(2):74-81. doi: 10.1055/s-0035-1549967.

PMID:
26158794
14.

Tofogliflozin: a highly selective SGLT2 inhibitor for the treatment of type 2 diabetes.

Rosenwasser RF, Rosenwasser JN, Sutton D, Choksi R, Epstein B.

Drugs Today (Barc). 2014 Nov;50(11):739-45. doi: 10.1358/dot.2014.50.11.2232267.

PMID:
25525634
15.

In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP.

Yamane M, Kawashima K, Yamaguchi K, Nagao S, Sato M, Suzuki M, Honda K, Hagita H, Kuhlmann O, Poirier A, Fowler S, Funk C, Simon S, Aso Y, Ikeda S, Ishigai M.

Xenobiotica. 2015 Mar;45(3):230-8. doi: 10.3109/00498254.2014.976296.

PMID:
25350082
16.

Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models.

Suzuki M, Takeda M, Kito A, Fukazawa M, Yata T, Yamamoto M, Nagata T, Fukuzawa T, Yamane M, Honda K, Suzuki Y, Kawabe Y.

Nutr Diabetes. 2014 Jul 7;4:e125. doi: 10.1038/nutd.2014.20.

17.

Tofogliflozin: first global approval.

Poole RM, Prossler JE.

Drugs. 2014 Jun;74(8):939-44. doi: 10.1007/s40265-014-0229-1.

PMID:
24848755
18.

Tofogliflozin: the road goes ever on.

Pafili K, Papanas N.

Expert Opin Pharmacother. 2014 Jun;15(9):1197-201. doi: 10.1517/14656566.2014.916278.

PMID:
24787286
19.

Competitive inhibition of SGLT2 by tofogliflozin or phlorizin induces urinary glucose excretion through extending splay in cynomolgus monkeys.

Nagata T, Suzuki M, Fukazawa M, Honda K, Yamane M, Yoshida A, Azabu H, Kitamura H, Toyota N, Suzuki Y, Kawabe Y.

Am J Physiol Renal Physiol. 2014 Jun 15;306(12):F1520-33. doi: 10.1152/ajprenal.00076.2014.

20.

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study.

Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K, Tanizawa Y, Araki E, Ueda M, Suganami H, Watanabe D; Tofogliflozin 003 Study Group..

Cardiovasc Diabetol. 2014 Mar 28;13:65. doi: 10.1186/1475-2840-13-65.

Items per page

Supplemental Content

Loading ...
Support Center